isunakinra

BIOLOGICAL2 trials

Sponsors

Buzzard Pharmaceuticals

Conditions

Colorectal Cancer MetastaticSolid Tumor, Adult

Phase 1

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

CompletedNCT04121442

Buzzard PharmaceuticalsSolid Tumor, Adult

Start: 2020-09-01End: 2024-07-15Updated: 2024-08-06

Phase 2

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

RecruitingNCT06634875

Buzzard PharmaceuticalsColorectal Cancer Metastatic

Start: 2025-01-30End: 2026-12-01Target: 20Updated: 2026-03-31

Related Papers

A phase I study of isunakinra, an IL-1 alfa/beta inhibitor, in combination with nivolumab for patients with solid tumors refractory to standard therapies.

Journal of Clinical Oncology2023-06-012 citations